


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 14, 2003

Signature: 
(Thomas J. Wrona, Ph.D.)

11/B 5/20

Docket No.: 30566/30029
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Rosanne M. Crooke, *et al.*

Application No.: 09/920,033

Group Art Unit: 1635

Filed: August 1, 2001

Examiner: J. Epps

For: ANTISENSE MODULATION OF
APOLIPOPROTEIN B EXPRESSION

RECEIVED
MAY 19 2003
TECH CENTER 1600/2900

**I. AMENDMENT AND II. RESPONSE TO THE OFFICE ACTION
OF JANUARY 14, 2003**


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I. AMENDMENT

Please amend the above-identified U.S. patent application as follows:

In the Claims

- 
1. (Twice Amended) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B [(SEQ ID NO: 3)], wherein said compound specifically hybridizes with nucleotides 1-128 or nucleotides 149-14121 as set forth in SEQ ID NO: 3 and inhibits the expression of a nucleic acid molecule encoding apolipoprotein B.
 2. (Original) The compound of claim 1 which is an antisense oligonucleotides.
 3. (Canceled)
 4. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.